UBS initiated coverage on AtriCure with a new price target
$ATRC
Medical/Dental Instruments
Health Care
UBS initiated coverage of AtriCure with a rating of Buy and set a new price target of $56.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2026 | $36.00 | Overweight → Neutral | Analyst |
| 12/17/2024 | $40.00 | Overweight | Analyst |
| 4/23/2024 | $32.00 | Perform → Outperform | Oppenheimer |
| 10/23/2023 | $60.00 | Mkt Outperform | JMP Securities |
| 9/29/2023 | $56.00 | Buy | UBS |
| 2/16/2022 | $120.00 → $88.00 | Buy | Canaccord Genuity |
| 2/16/2022 | $92.00 → $79.00 | Buy | Needham |
| 11/4/2021 | $90.00 → $92.00 | Buy | Needham |
8-K - AtriCure, Inc. (0001323885) (Filer)
8-K - AtriCure, Inc. (0001323885) (Filer)
144 - AtriCure, Inc. (0001323885) (Subject)
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio
VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]. This systemic re-rating is driven by healthcare's structural pivot from bulky, expensive hardware to agile, software-defined intelligence. As diagnostics move out of specialized labs and into decentralized, point-of-care environments[2], institutions are rotating capital into a first-mover cohort capable of delivering MRI-grade accuracy on the fly. This secular transition is positioning VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Heartflow (NASDAQ:HTFL), AtriCure (NASDAQ:ATRC), Edwards
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quarter of 2024 (12% on a constant currency basis). U.S. revenue is expected to be $114.3 million, reflecting growth of approximately 13%, and international revenue is expected to be $26.2 million, an increase of approximately 15% as
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
Analyst downgraded AtriCure from Overweight to Neutral and set a new price target of $36.00
Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00
Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00
4 - AtriCure, Inc. (0001323885) (Issuer)
SC 13G - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)